• 中国科技论文统计源期刊
  • 中国科技核心期刊
  • 中国高校优秀期刊
  • 安徽省优秀科技期刊

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

UGT1A1基因多态性与伊立替康治疗晚期胃肠道肿瘤不良反应和疗效的相关性分析

刘静 ,  刘杨 ,  赵福友 ,  汪蕊 ,  李玉梅

downloadPDF
文章导航 > 蚌埠医学院学报  > 2017,  42 > 8: (1017-1021)  
引用本文:
shu
Citation:
shu

UGT1A1基因多态性与伊立替康治疗晚期胃肠道肿瘤不良反应和疗效的相关性分析

  • 蚌埠医学院第一附属医院 肿瘤内科, 安徽 蚌埠 233004

    • 作者简介: 刘静(1988-),女,硕士研究生.
    通讯作者: 李玉梅, 主治医师.liyumei198311@126.com
  • 基金项目:

    蚌埠医学院研究生科研创新计划项目（Byycxz1415）；蚌埠医学院自然科学基金项目（Byky1331）

  • 中图分类号: R735.35

Correlation analysis between UGT1A1 gene polymorphism,and the toxicity and efficacy of irinotecan in the treatment of advanced gastrointestinal cancer

  • Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu Anhui 233004, China

    • Corresponding author: LI Yu-mei, 主治医师.liyumei198311@126.com

  • CLC number: R735.35

  • 摘要: 目的：探讨尿苷二磷酸葡糖苷酸转移酶1A1（UGT1A1）基因多态性与伊立替康治疗晚期胃肠道肿瘤不良反应和疗效的关系。方法：在62例含伊立替康方案化疗的晚期胃肠道肿瘤病人化疗前，使用PCR-HRM法获取研究对象的外周血并检测UGT1A1基因型，分析UGT1A1基因多态性与化疗不良反应、疗效的相关性。结果：UGT1A1*28位点野生型（TA6/6）、杂合突变型（TA6/7）、纯合突变型（TA7/7）分布频率分别是77.4%、11.3%、11.3%；UGT1A1*6位点野生型（G/G）占79.1%，杂合突变型（G/A）占16.1%，纯合突变型（A/A）占4.8%。UGT1A1*28和UGT1A1*6突变型均较其野生型增加了病人发生3级以上腹泻和中性粒细胞减少的风险（P<0.05~P<0.01）。UGT1A1各基因型之间的疗效差异均无统计学意义（P>0.05）。结论：在含伊立替康方案治疗的晚期胃肠道肿瘤中，UGT1A1*28和UGT1A1*6的突变可以作为伊立替康相关严重延迟性腹泻和中性粒细胞减少的预测指标。未发现UGT1A1基因多态性与疗效之间存在相关性。
    Abstract: Objective:To investigate the correlations between uridine-diphosphoglucuronate glucuronosyltransferase 1 family polypetide A1(UGT1A1) gene polymorphism,and the toxicity and efficacy of irinotecan in the treatment of advanced gastrointestinal cancer.Methods:The UGT1A1 genotypes in 62 advanced gastrointestinal cancer patients before treatment with irinotecan were detected using the polymerase chain reaction and high-resolution melting analysis.The correlations between UGT1A1 gene polymorphisms,and the toxicity and efficacy of irinotecan were analyzed.Results:The distribution frequency of wild-type(TA6/6),heterozygous mutant-type(TA6/7) and homozygous mutant-type(TA7/7) in UGT1A1*28 loci were 77.4%,11.3%,and 11.3%,respectively.The proportion of wild-type(G/G),heterozygous mutant-type(G/A) and homozygous mutant-type(A/A) in UGT1A1*6 loci were 79.1%,16.1% and 4.8%,respectively.Compared with the wild types of UGT1A1*28 and UGT1A1*6,the risks of the more than grade 3 diarrhea and neutropenia in mutant types of UGT1A1*28 and UGT1A1*6 increased(P<0.05 to P<0.01).The difference of the efficacy between different genotypes of UGT1A1 was not statistically significant(P>0.05).Conclusions:During the irinotecan in the treatment of advanced gastrointestinal cancer,the locus mutations of UGT1A1*28 and UGT1A1*6 can be regarded as the predictors of irinotecan-associated severe delayed diarrhea and neutropenia.The correlation between UGT1A1 gene polymorphism and efficacy of irinotecan is not found.
  • [1] OHE Y,OHASHI Y,KUBOTA,et al.Randomized phase Ⅲ study of cisplatin plus irinotecan versus carboplatin plus paclitaxel,cisplatin plus gemcitabine,and cisplatin plus vinorelbine for advanced non-small-cell lung cancer:Four-Arm Cooperative Study in Japan[J].Ann Oncol,2007,18(2):317.
    [2] SHOJI T,TAKATORI E,OMI H,et al.Phase Ⅱ clinical study of the combination chemotherapy regimen of irinotecan plus oral etoposide for the treatment of recurrent ovarian cancer(Tohoku Gynecologic Cancer Unit 101 Group Study)[J].Int J Gynecol Cancer,2011,21(1):44.
    [3] ZHOU CF,MA T,SU Y,et al.UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer[J].Anticancer Agents Med Chem,2013,13(2):235.
    [4] XIE FW,PENG YH,WANG WW,et al.Influence of UGT1A1 gene methylation level in colorectal cancer cells on the sensitivity of the chemotherapy drug CPT-11[J].Biomed Pharmacother,2014,68(7):825.
    [5] SCHULZ C,BOECK S,HEINEMANN V,et al.UGTlAl genotyping:a predictor of irinotecan-associated side effects and drug efficacy[J].Anticancer Drugs,2009,20(10):867.
    [6] HIROSE K,KOZU C,YAMASHITA K,et al.Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene[J].Oncol Lett,2012,3(3):694.
    [7] DESAI AA,INNOCENTI F,RATAIN MJ.Pharmacogenomics:road to anticancer therapeutics nirvana[J].Oncogene,2003,22(42):6621.
    [8] PARK SR,KONG SY,RHEE J,et al.Phase Ⅱ study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer:clinical and pharmacogenetic results[J].Ann Oncol,2011,22(4):890.
    [9] TAKANO M,KATO M,YOSHIKAWA T,et al.Clinical signifiance of UDPglucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers:a prospective multi-institutional study[J].Oncology,2009,76(5):315.
    [10] MINAMI H,SAI K,SAEKI M,et al.Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese:roles of UGT1A1*6 and *28[J].Pharmacogenet Genomics,2007,17(7):497.
    [11] ONOUE M,TERADA T,KOBAYASHI M,et al.UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients[J].Int J Clin Oncol,2009,14(2):136.
    [12] LI M,WANG Z,GUO J,et al.Clinical signifiance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer[J].Onco Targets Ther,2014,7:1653.
    [13] STEWART CF,PANETTA JC,O'SHAUGHNESSY MA,et al.UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics,but not severe toxicity in patients receiving low-dose Irinotecan[J].J Clin Oncol,2007,25(18):2594.
    [14] HOSKINS JM,GOLDBERG RM,Qu P,et al.UGT1A1*28 genotype and irinotecan-induced neutropenia:dose matters[J].J Natl Cancer Inst,2007,99(17):1290.
    [15] SUGIYAMA T,HIROSE T,KUSUMOTO S,et al.The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer[J].Oncol Res,2010,18(7):337.
    [16] TZIOTOU M,KALOTYCHOU,NTOKOU A.Polymorphisms of uridine glucuronosyltransferase gene and irinotecan toxicity:low dose does not protect from toxicity[J].Ecancermedicalscience,2014,8:428.
    [17] HU ZY,YU Q,PEI Q,et al.Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia:low doses also increase risk[J].Clin Cancer Res,2010,16(15):3832.
    [18] SAI K,SAWADA J,MINAMI H.Irinotecan pharmacogenetics in Japanese cancer patients:roles of UGT1A1*6 and *28[J].Yakugaku Zasshi,2008,128(4):575.
    [19] DI PAOLO A,BOCCI G,POLILLO M,et al.Pharmaeokinetie and pharmaeo-genetic predictive markers of irinoteean activity and toxicity[J].Curr Drug Metab,2011,12(10):932.
    [20] MARQUES SC,IKEDIOBI ON.The clinical application of UGTlAl pharmaeogenetic testing:gene-environment interactions[J].Hum Genomics,2010,4(4):238.
    [21] MCLEOD HL,SARGENT DJ,MARSH S,et al.Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer:results from North American Gastrointestinal Intergroup Trial N9741[J].J Clin Oncol,2010,28(20):3227.
    [22] GLIMELIUS B,GARMO H,BERGLUND A,et al.Prediction of irinotecan and 5-florouracil toxicity and response in patients with advanced colorectal cancer[J].Pharmacogenomics J,2011,11(1):61.
    [23] TAKAHARA N,NAKAI Y,ISAYAMA H,et al.Uridine diphosphate glucuronosyl transferase 1 family polypetide A1 gene(UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer[J].Cancer Chemother Pharmacol,2013,71(1):85.
  • [1] 李玉梅 , 刘静 , 赵福友 , 周争光 , 吴穷 . 伊立替康联合雷替曲塞3周方案二线治疗晚期结直肠癌的疗效观察. 蚌埠医学院学报, 2017, 42(8): 1029-1031,1035. doi: 10.13898/j.cnki.issn.1000-2200.2017.08.005
    [2] 耿建 , 石玉荣 , 王慧 , 秦蓉 . 细胞色素P450 1A1基因Ile/Val多态性与子宫颈癌的遗传易感性研究. 蚌埠医学院学报, 2010, 35(8): 762-763,767.
    [3] 高磊 , 冯崴 , 王廷涛 , 王茂松 . 血管紧张素Ⅱ受体1基因多态性与高血压合并心肌梗死发生的相关性. 蚌埠医学院学报, 2022, 47(1): 30-32. doi: 10.13898/j.cnki.issn.1000-2200.2022.01.007
    [4] 李涛 , 赖春凤 , 丘波 , 邹浩元 , 杨宇辉 . CYP2E1基因rs3813867位点多态性与客家人群胃癌遗传易感性的研究. 蚌埠医学院学报, 2017, 42(11): 1446-1449. doi: 10.13898/j.cnki.issn.1000-2200.2017.11.005
    [5] 王剑南 , 杨兆宁 , 隋强 . 5-脂氧合酶激活蛋白及磷酸二酯酶4D基因多态性与脑梗死易患性的分子流行病学研究. 蚌埠医学院学报, 2015, 40(10): 1338-1340.
    [6] 赵保明 , 赵莉 , 贺文欣 , 王元元 , 李徽徽 , 周艳梅 . 亚甲基四氢叶酸还原酶基因多态性与2型糖尿病的相关性. 蚌埠医学院学报, 2014, 38(2): 155-157.
    [7] 崔红青 . 伊立替康联合顺铂治疗晚期肺癌护理体会. 蚌埠医学院学报, 2011, 36(5): 527-528.
    [8] 孙翠玲 , 胡文军 . 伊立替康联合氟尿嘧啶/亚叶酸钙治疗晚期大肠癌疗效分析. 蚌埠医学院学报, 2010, 35(5): 459-460.
    [9] 屈艳艳 . 心理干预对胃肠道肿瘤化疗患者负性情绪的影响. 蚌埠医学院学报, 2016, 41(6): 840-841. doi: 10.13898/j.cnki.issn.1000-2200.2016.06.045
    [10] 廖亚平 , 鲍明升 , 梁玉华 . 叶酸代谢相关基因多态性与Down综合征发生的关系. 蚌埠医学院学报, 2009, 34(10): 949-951.
    [11] 孙思雨 , 尚茂林 . 蚌埠地区高血压病人药物基因多态性的分布. 蚌埠医学院学报, 2022, 47(7): 912-916. doi: 10.13898/j.cnki.issn.1000-2200.2022.07.018
    [12] 查秀婧 , 毕娅欣 . 细胞毒性T淋巴细胞相关抗原-4基因多态性与Graves病复发的相关性研究. 蚌埠医学院学报, 2015, 40(1): 14-16. doi: 10.13898/j.cnki.issn.1000-2200.2015.01.005
    [13] 陈昭琳 , 方焱 , 程希 , 冯晓俊 , 张蕾 , 唐丽琴 . IL-10和CYP3A5基因多态性对中国肾移植病人术后稳定期他克莫司血药浓度/剂量比的影响. 蚌埠医学院学报, 2021, 46(7): 841-845. doi: 10.13898/j.cnki.issn.1000-2200.2021.07.001
    [14] 竟雪莹 , 马根山 , 陈忠 . 纤维蛋白原β基因启动子-845G/A多态性与早发冠心病相关性. 蚌埠医学院学报, 2009, 34(3): 206-208.
    [15] 李惠 , 包宗明 . 髓过氧化物酶-463G/A基因多态性与冠心病的易患关系. 蚌埠医学院学报, 2007, 32(6): 657-659.
    [16] 刘启玲 , 王志忠 , 张荣强 , 刘秀英 , 张志刚 . 宁夏地区老年人群载脂蛋白E等位基因ε4携带与血脂水平的相关性研究. 蚌埠医学院学报, 2017, 42(7): 841-844. doi: 10.13898/j.cnki.issn.1000-2200.2017.07.001
    [17] 王影 . 康复新防治奥沙利铂所致周围神经毒性的效果观察. 蚌埠医学院学报, 2015, 40(4): 536-537. doi: 10.13898/j.cnki.issn.1000-2200.2015.04.041
    [18] 许贵香 , 孙祥瑞 , 王亚男 , 朱显璋 , 吴华璞 . 2-(E)-取代苯亚甲基-5-二甲氨甲基环戊酮抗炎作用及胃肠道刺激性观察. 蚌埠医学院学报, 2006, 31(6): 601-603.
    [19] 常洁 , 林仲秋 . HLA-DQB1等位基因多态性与宫颈癌的关联性. 蚌埠医学院学报, 2013, 37(7): 781-783,786.
    [20] 钟辉 , 宋曾光 , 刘运贤 , 吴小龙 . 神经纤维瘤病1型相关的胃肠道间质瘤. 蚌埠医学院学报, 2010, 35(10): 1012-1014,1017.
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  3907
  • HTML全文浏览量:  521
  • PDF下载量:  93
  • 被引次数: 0
出版历程
  • 收稿日期:  2015-11-18

UGT1A1基因多态性与伊立替康治疗晚期胃肠道肿瘤不良反应和疗效的相关性分析

    通讯作者: 李玉梅, 主治医师.liyumei198311@126.com
    作者简介: 刘静(1988-),女,硕士研究生.
  • 蚌埠医学院第一附属医院 肿瘤内科, 安徽 蚌埠 233004
  • 收稿日期: 2015-11-18
基金项目:  蚌埠医学院研究生科研创新计划项目（Byycxz1415）；蚌埠医学院自然科学基金项目（Byky1331）

摘要: 目的：探讨尿苷二磷酸葡糖苷酸转移酶1A1（UGT1A1）基因多态性与伊立替康治疗晚期胃肠道肿瘤不良反应和疗效的关系。方法：在62例含伊立替康方案化疗的晚期胃肠道肿瘤病人化疗前，使用PCR-HRM法获取研究对象的外周血并检测UGT1A1基因型，分析UGT1A1基因多态性与化疗不良反应、疗效的相关性。结果：UGT1A1*28位点野生型（TA6/6）、杂合突变型（TA6/7）、纯合突变型（TA7/7）分布频率分别是77.4%、11.3%、11.3%；UGT1A1*6位点野生型（G/G）占79.1%，杂合突变型（G/A）占16.1%，纯合突变型（A/A）占4.8%。UGT1A1*28和UGT1A1*6突变型均较其野生型增加了病人发生3级以上腹泻和中性粒细胞减少的风险（P<0.05~P<0.01）。UGT1A1各基因型之间的疗效差异均无统计学意义（P>0.05）。结论：在含伊立替康方案治疗的晚期胃肠道肿瘤中，UGT1A1*28和UGT1A1*6的突变可以作为伊立替康相关严重延迟性腹泻和中性粒细胞减少的预测指标。未发现UGT1A1基因多态性与疗效之间存在相关性。

English Abstract

    全文HTML

参考文献 (23)

目录

    /

    返回文章
    返回

    版权所有© 2019《蚌埠医学院学报》编辑部 皖ICP备06000434号-1

    地址：安徽省蚌埠市东海大道2600号 邮编：233030

    电话：0552-3175456 Email：byxb@vip.163.com

    本系统由 北京仁和汇智信息技术有限公司 开发 技术支持： info@rhhz.net   百度统计